A post hoc analysis of the PARADIGM-HF trial further suggests, to a certain extent, that lower doses of S/V can reduce heart failure-related mortality and morbidity compared to equivalent doses of ACE inhibitors, as it did not demonstrate a significant heterogeneity of treatment effect by dose. The gene discussed is ACE; the disease is heart failure.